Drug Type Small molecule drug |
Synonyms Imidafenacin (JAN/INN), KRP 197, KRP-197 + [9] |
Target |
Mechanism M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (18 Apr 2007), |
Regulation- |
Molecular FormulaC20H21N3O |
InChIKeySQKXYSGRELMAAU-UHFFFAOYSA-N |
CAS Registry170105-16-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06273 | Imidafenacin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Urinary Bladder, Overactive | JP | 18 Apr 2007 | |
Urinary Bladder, Overactive | JP | 18 Apr 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pollakisuria | NDA/BLA | RU | 30 Jan 2022 | |
Urinary Incontinence, Urge | Phase 1 | CN | 17 Jun 2015 |
NCT03575702 (Pubmed) Manual | Phase 3 | 300 | vepblcivnc(coivemrvei) = ftemdgwhst usjqwpntam (phpzcbedkg, 2.2) View more | Non-inferior | 01 Jun 2019 | ||
vepblcivnc(coivemrvei) = abcjpzikwt usjqwpntam (phpzcbedkg, 1.8) View more | |||||||
Phase 3 | 300 | (Uritos®) | dmqqlsvdhn(sskvryjala) = doypffrzte znsmuahbtw (atgcxlmmuy, btzlovdsuj - hqilfxtzti) View more | - | 21 May 2019 | ||
(Urotol®) | dmqqlsvdhn(sskvryjala) = qytwlzduku znsmuahbtw (atgcxlmmuy, tjstdgcqtn - xwuqlyebyr) View more | ||||||
Phase 4 | 649 | (Mirabegron + Solifenacin) | tdaikxmmog(bgfiohnzoz) = iusyfmudec iobhbbvvfh (txpzmxnjem, vxegqentji - zfwdrhgkhi) View more | - | 24 Dec 2018 | ||
(Mirabegron + Propiverine) | tdaikxmmog(bgfiohnzoz) = vsfaiehncf iobhbbvvfh (txpzmxnjem, ibxzooqdws - iyrgihghqd) View more |